in March 2006, six healthy volunteers underwent cytokine-induced injury and multiorgan failure from a Phase 1 first-in-human drug trial with a novel monoclonal antibody. This talk describes the clinical and incident management ramifications, drawing connections to other non-conventional incidents which may pose a different pattern of clinical, operational and communications challenges to the 'classic' trauma-based model of major incidents.